RAD51D胚系突变与BRCA1/2阴性乳腺癌风险及生存的关联
该研究在7657例BRCA1/2胚系突变阴性的未选择性乳腺癌患者中检测RAD51D胚系突变,并在7947例健康对照中筛检复发性突变p.K91fs。结果发现p.K91fs与乳腺癌风险中度升高相关(OR=2.34),且RAD51D突变携带者诊断年龄更轻、更易为三阴性及高级别肿瘤,无复发生存和远端无复发生存均更差。
要点
- RAD51D致病性胚系突变在BRCA1/2阴性未选择性乳腺癌中占0.38%。
- 复发性突变p.K91fs与乳腺癌风险中度升高相关(OR=2.34,95%CI 1.02-5.38;P=0.040)。
- RAD51D突变携带者无复发生存(HR=3.00)和远端无复发生存(HR=2.54)显著更差。
核心结论
- RAD51D复发性突变p.K91fs中度增加乳腺癌风险,且RAD51D突变携带者生存预后较非携带者差。
研究设计与样本
- 在7657例BRCA1/2胚系突变阴性的未选择性乳腺癌患者中,采用多基因panel检测RAD51D胚系突变。
- 通过Sanger测序在7947例健康对照中筛检RAD51D复发性突变p.K91fs。
主要发现
- 7657例患者中29例(0.38%)携带RAD51D致病性胚系突变,其中18例(0.24%)携带p.K91fs。
- 7947例健康对照中8例(0.10%)携带p.K91fs突变。
- p.K91fs与未选择性乳腺癌风险升高显著相关(OR=2.34,95%CI 1.02-5.38;P=0.040)。
- RAD51D突变携带者较非携带者诊断年龄更轻(P=0.006),更易为三阴性乳腺癌(P=0.003)、雌激素受体阴性(P=0.005)和高级别肿瘤(P=0.023)。
- RAD51D突变携带者的无复发生存(未校正HR=3.00,95%CI 1.56-5.80;P=0.001)和远端无复发生存(未校正HR=2.54,95%CI 1.14-5.67;P=0.023)显著更差。
临床怎么用
- 对BRCA1/2阴性乳腺癌患者,可考虑RAD51D胚系检测以评估遗传风险。
- RAD51D突变携带者预后较差,需加强随访和复发监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: RAD51D is involved in DNA double-strand break repair by homologous recombination and plays an important role in the maintenance of genomic stability. The associations between RAD51D germline mutations and breast cancer risk and survival are not fully elucidated. PATIENTS AND METHODS: RAD51D germline mutations were determined using a multigene panel in 7657 unselected breast cancer patients who were negative for BRCA1/2 germline mutations. The RAD51D recurrent mutation p.K91fs was screened in 7947 healthy controls by Sanger sequencing. RESULTS: A total of 29 cases (0.38%) carried deleterious RAD51D germline mutations among this cohort of 7657 unselected breast cancer patients. The RAD51D recurrent mutation p.K91fs was identified in 18 cases (0.24%) of these 7657 patients. In contrast, the p.K91fs mutation was found in 8 of 7947 healthy controls with a frequency of 0.10%. The RAD51D p.K91fs mutation was significantly associated with increased breast cancer risk in unselected breast cancer [odds ratio = 2.34, 95% confidence interval (CI) 1.02-5.38; P = 0.040]. RAD51D mutation carriers were diagnosed at a younger age (P = 0.006) and were more likely to be triple-negative breast cancer (P = 0.003), estrogen receptor negative (P = 0.005) and high-grade cancers (P = 0.023) than noncarriers. Furthermore, RAD51D mutation carriers had a significantly worse recurrence-free survival [unadjusted hazard ratio (HR) = 3.00, 95% CI 1.56-5.80; P = 0.001] and distant recurrence-free survival (unadjusted HR = 2.54, 95% CI 1.14-5.67; P = 0.023) than noncarriers. CONCLUSION: The RAD51D recurrent mutation, p.K91fs, confers a moderately increased breast cancer risk, and RAD51D mutation carriers have an unfavorable survival compared with noncarriers.
引用
- Chen X, Li Y, Ouyang T, et al. Associations between RAD51D germline mutations and breast cancer risk and survival in BRCA1/2-negative breast cancers. Ann Oncol. 2018. PMID: 30165555. doi:10.1093/annonc/mdy338
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。